Phosphorylated PSAT1 Inhibitor

Sensitizes PD-1 Therapy

Inhibiting PSAT1 phosphorylation at S337 enhances IFNγ-induced ferroptosis and improves response to PD-1 blockade in triple-negative breast cancer.

Zheng, Peixiang · Hu, Zhiqiang · Yuli, Shen · Gu, Lina · Ouyang, Yuan · Yuran, Duan · Guimei, Ji · Bofei, Dong · Lin, Yanni · Ting, Wen · Tian, Qi · Yueru, Hou · Zhou, Qimin · Sun, Xue · Xiaohan, Chen · Luo, Shudi · Shiqi, Wu · Li, Min · Liwei, Xiao · Wu, Qingang · Meng, Ying · Guijun, Liu · Wang, Zheng · Bai, Xueli · Shengzhong, Duan · Ding, Yuan · Yuhao, Wang · Liu, Xiaoguang · Lu, Zhimin · Xiaohong, Wu · Tang, Zhiyuan · Xu, Daqian

Nature Chemical Biology 2025

Advantages

Blocking PSAT1 pS337 enhances IFNγ-induced ferroptosis and improves PD-1 antibody efficacy

Reconstitution of PSAT1 S337A or GPX4 P159A promotes ferroptosis and suppresses TNBC progression

PSAT1-mediated GPX4 hydroxylation correlates with poor immunotherapy outcomes in TNBC patients